Showing results (91-100 of 108) with videos related to
Sort By:
Pageof 11
Haematologica|September 11, 2025
IGLV3-21<sup>R110</sup>-directed bispecific antibodies activate T cells and promote killing in a high-risk subset of chronic lymphocytic leukemiaClaudia Fischer, Shih-Shih Chen, Johanna Nimmerfroh, et al.Chest|March 31, 2012
Lung resection in hematologic patients with pulmonary invasive fungal diseaseChristian A Nebiker, Didier Lardinois, Lilian Junker, et al.Blood|February 1, 2007
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phaseFrancois Guilhot, Jane Apperley, Dong-Wook Kim, et al.Bone Marrow Transplantation|November 4, 2018
Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry studyGuido Ghilardi, Thomas Pabst, Barbara Jeker, et al.Annals of Hematology|March 11, 2021
Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohortMagdalena M Brune, Georg Stüssi, Pontus Lundberg, et al.The New England Journal of Medicine|September 15, 2016
Rituximab in B-Lineage Adult Acute Lymphoblastic LeukemiaSébastien Maury, Sylvie Chevret, Xavier Thomas, et al.Leukemia|February 27, 2018
Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IVSusanne Saussele, Rüdiger Hehlmann, Alice Fabarius, et al.Hematological Oncology|December 7, 2023
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021Jakob R Passweg, Helen Baldomero, Marc Ansari, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2009
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trialJane F Apperley, Jorge E Cortes, Dong-Wook Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 3, 2017
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)Nicolaus Kröger, Simona Iacobelli, Georg-Nikolaus Franke, et al.Pageof 11